The Uromigos Episode 158: ASCO GU 2022 PROpel Phase III Olaparib and Abiraterone in mCRPC

By The Uromigos - Last Updated: November 11, 2022

Dr. Fred Saad describes the results of the PROpel Phase III trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC.

Post Tags:Uromigos-ASCO GUUromigos-Prostate Cancer
Advertisement

Related Podcasts

Episode 310: Dosing and Duration of Drugs From a Cost Perspective
Uromigos-Prostate Cancer
Episode 309: EAU 24 CheckMate-274 - OS for Adjuvant Nivolumab
Uromigos-Bladder Cancer
Episode 308: EAU 24 IMvigor011 - Outcome of ctDNA-Negative Patients Post-Cystectomy
Uromigos-Bladder Cancer
Episode 307: Bladder-Sparing Approaches Part 2
Uromigos-Bladder Cancer
Episode 306: Chemo/Nivo as a Bladder Sparing Approach in UC
Uromigos-Bladder Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC. All rights reserved.

    Terms of Use | Privacy Policy